Abstract: Peptide analogues of insulin-like growth factor 1 and growth factor 2 are disclosed. When the analogue is an analogue of growth factor 1 the glutamic acid residue is absent from position 3 of the N-terminal and either the glutamic acid residue or the threonine residue adjacent to glutamic acid residue at position 3 is replaced by a different amino acid residue. When the peptide analogue is an analogue of insulin growth factor 2 the glutamic acid residue position 5 is absent. Preferred peptide analogues are disclosed. Methods of use in pharmaceutical and veterinary preparations are described.

Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.

Abstract: Novel synthetic polypeptide derivatives, i.e., novel calcitonin derivatives, having improved basic physiological activities of the corresponding natural calcitonins, i.e., the activity for lowering the blood level of calcium, the activity as an analgesic, as well as the activity for inhibiting the secretion of the gastric juice. Thus these synthetic calcitonins are effective as agents for curing hypercalcemia, analgetic agents, anti-ulcerative agents and the like.

Abstract: The invention is a method of synthesizing tetrahydropteroylpoly-L-glutamic acid derivatives starting from the mono-L-glutamic acid derivatives. The method has the advantage of not requiring any enzymes.

Abstract: Tripeptide derivatives of formula (I) such as N-.epsilon.-(p-tosyl)-D-lysyl-L-prolyl-L-argininal have an activity of inhibiting a plurality of trypsin-like serine proteases, e.g., plasmin, thrombin, trypsin, kallikrein, factor Xa, urokinase, etc. in vivo. The tripeptide derivatives can be expected as novel protease inhibitors due to their remarkable pharmaceutical effects.

Abstract: Novel reagent compositions and an assay method for the measurement of total and direct bilirubin are disclosed. The reagent compositions comprise an aqueous solution of at least one betaine selected from the group of alkyl betaine, betaine and betaine hydrate, a sulfanilamide diazonium salt, iodide ions and sulfamic acid. In the measurement of total bilirubin, alkyl betaine serves as an accelerator/solubilizer for the reaction of unconjugated bilirubin, and the alkyl betaine, betaine or betaine hydrate, together with iodide ions, minimizes or substantially eliminates interference from hemoglobin and lipemia.

Abstract: Novel human insulin analogs exhibiting high biological activity and in which the amino acid residue Phe.sup.B25 is substituted by His or Tyr and moreover substitutions may optionally be present in one or more of the positions A4, A8, A17, A21, B9, B10, B12, B13, B21, B26, B27, B28, and B30, as well as the amino acid residue in the B30 position may further be totally missing or may be blocked at the C-terminal in the form of ester or amide.

Abstract: The invention relates to insulin derivatives of the formula III ##STR1## in which R.sup.30 and R.sup.31 together are OH, or R.sup.30 is a radical of a neutral, genetically encodable L-amino acid and R.sup.31 is OH or a physiologically acceptable organic group of basic character having up to 50 carbon atoms, whose synthesis involves 0 to 3 .alpha.-amino acids and whose optional terminal carboxyl function can be present free, as an ester function, as an amide function, as a lactone or reduced to CH.sub.2 OH, and R.sup.A-1 is a radical of a genetically encodable L-amino acid, and physiologically acceptable salts of said insulin derivative of the formula III.

Abstract: Disclosed is a rinse for preservation solution for organs and tissues selected for transplantation. The solution can be used at all temperatures from 0.degree. C. to normal body temperature and continues to be protective above 10.degree. C. Methods for preparing organs and tissues preserved in a preservation solution prior to transplant into a recipient are also disclosed.

Abstract: The present invention provides a method for preparing aqueous formulations of thymopentin, which method permits the peptide to retain its biological activity during storage at room temperature.

Abstract: A synthetic peptide corresponding to the following formula:X--Asp--Y--DTrp--Val--DTrp--Z--K--NH.sub.2where:X=H, Arg, DArg, Lys, DLys, Thr, DThrY=Tyr, Trp, DTrp, Ser, MetZ=Trp, DTrpK=Arg, Phe, DTrp, Tyr, Metand pharmaceutically acceptable salts thereof with organic and inorganic acids as competitive antagonists against neurokinin A (NK-2 receptor).

Abstract: Novel blood coagulation inhibitors are disclosed which are peptide fragments comprising (A) Kunitz-type domain two of lipoprotein-associated coagulation inhibitor which inhibits Factor Xa production and (B) Kunitz-type domains one and two of lipoprotein-associated coagulation inhibitor which inhibits Factor VIIa/TF enzymatic complex formation.

Abstract: In the esterification of glutathione with alcohol in the presence of acid catalyst, neutral glutathione monoester is isolated in high yields without the intermedite isolation of ester acid salt by treating the reaction mixture with base anion exchange resin (basic form) to neutralize the acid and bind the resulting acid anion and unesterified glutatione. Dehydrating agent is used to drive the reaction toward esterification. In the production of glutathione monester acid salts a soluble dehydrating agent is advantageously used.